CURIS INC (CRIS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2312693094
CURIS INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 9.44 m USD |
| Operating income | -5.71 m USD |
| EBIT | -7.90 m USD |
| Net income | -7.58 m USD |
| Diluted EPS – continuing operations | -0.58 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CURIS INC
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
More stocks
- Reliance Global Group, Inc. (EZRA)
- Singularity Future Technology Ltd. (SGLY)
- WEED, INC. (BUDZ)
- Dermata Therapeutics, Inc. (DRMA)
- BestGofer Inc. (BGFR)
- MKDWELL Tech Inc. Ordinary Share (MKDW)
- Jet.AI Inc. (JTAI)
- Ernexa Therapeutics Inc. (ERNA)
- Arrive AI Inc. (ARAI)
- Techlott Inc. (LOTT)
- CALLAN JMB INC. (CJMB)
- ZW Data Action Technologies Inc. (CNET)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.